GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

APYX · Sep 30, 2025

Apyx Medical Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-25-033499General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

291.22% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity100thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

4.03% · OPTIONAL · VALID

Operating cash generation58thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-27.46% · OPTIONAL · VALID

Revenue growth75thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

12.10% · CORE · VALID

Inventory pressure25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

71.02% · OPTIONAL · VALID

Gross margin67thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

64.43% · CORE · VALID

Operating margin100thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-6.46% · CORE · VALID

R&D intensity0thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

6.22% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.12% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/9 normalizedLevel 3Dec 31, 20247/9 normalizedLevel 3Mar 31, 20257/9 normalizedLevel 3Jun 30, 20257/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
329.73%
Current
291.22%
Delta
-38.51%
Capex Intensity Increased
Previous
2.33%
Current
4.03%
Delta
1.70%
Cash Generation Decreased
Previous
-10.84%
Current
-27.46%
Delta
-16.62%
Growth Increased
Previous
-6.39%
Current
12.10%
Delta
18.49%
Inventory Pressure Decreased
Previous
72.03%
Current
71.02%
Delta
-1.01%
Margin Increased
Previous
62.28%
Current
64.43%
Delta
2.15%
Profitability Increased
Previous
-22.63%
Current
-6.46%
Delta
16.17%
R And D Intensity Decreased
Previous
7.25%
Current
6.22%
Delta
-1.02%
Sbc Intensity Decreased
Previous
4.57%
Current
4.12%
Delta
-0.46%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · APYX Fundamental State →Transitioned To · APYX Fundamental State →Transitioned To · APYX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · APYX CAPEX_INTENSITY_INCREASED →Transitioned To · APYX CASH_GENERATION_DECREASED →Transitioned To · APYX GROWTH_INCREASED →Transitioned To · APYX INVENTORY_PRESSURE_DECREASED →Transitioned To · APYX MARGIN_INCREASED →Transitioned To · APYX PROFITABILITY_INCREASED →Transitioned To · APYX R_AND_D_INTENSITY_DECREASED →Transitioned To · APYX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.